Land: New Zealand
Sprog: engelsk
Kilde: Medsafe (Medicines Safety Authority)
Ethinylestradiol 0.01mg
New Zealand Medical & Scientific Ltd
Ethinylestradiol 0.01 mg
0.01 mg
Tablet
Active: Ethinylestradiol 0.01mg Excipient: Acacia Alginic acid Ethanol Lactose monohydrate Magnesium stearate Potato starch Water
Bottle, plastic, 100 tablets
Prescription
Prescription
Sanofi Chimie
Postmenopausal symptoms due to oestrogen deficiency including prevention of postmenopausal osteoporosis. In women with an intact uterus the addition of a progestogen is essential
Package - Contents - Shelf Life: Bottle, plastic, HDPE with PP cap with two piece induction seal foil wad - 100 tablets - 60 months from date of manufacture stored at or below 25°C
1969-12-31
NEW ZEALAND DATASHEET 1. PRODUCT NAME Ethinyloestradiol tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Ethinyloestradiol 10mcg. For excipients see 6.1. 3. PHARMACEUTICAL FORM Round white biconvex unscored tablets. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Postmenopausal symptoms due to oestrogen deficiency including prevention of postmenopausal osteoporosis. In women with an intact uterus the addition of a progestogen is essential. Treatment of metastatic breast cancer in postmenopausal women. Treatment of prostatic cancer. 4.2 Dose and method of administration This will depend on the particular indication used, but treatment should be undertaken with as low a dose as possible and for as short a period as is necessary. _ _ _Post _ _menopausal _ _symptoms _ _due _ _to _ _oestrogen _ _deficiency _ _including _ _prevention _ _of _ _postmenopausal osteoporosis:_ the usual dose range is 0.01-0.05mg daily, usually on a cyclical basis (e.g. 3 weeks on and 1 week off). For women without a uterus, who did not have endometriosis diagnosed, it is not recommended to add a progestogen. In women with an intact uterus (or in endometriosis when endometrial foci may be present despite hysterectomy), where a progestogen is necessary, it should be added for at least 12–14 days every month/28 day cycle to reduce the risk to the endometrium. The benefits of the lower risk of hyperplasia and endometrial cancer due to adding progestogen should be weighed against the increased risk of breast cancer (see Warnings and Precautions, and Adverse Effects). Therapy with ethinyloestradiol tablets may start at any time in women with established amenorrhoea or who are experiencing long intervals between spontaneous menses. In women who are menstruating, it is advised that therapy starts on the first day of bleeding. As ethinyloestradiol tablets are usually taken on a cyclical basis direct switching from other oestrogen-only HRT preparations taken cyclically is possible. _ _ _Treatment of prostatic cancer:_ 1-2mg daily. 4.3 Contra Læs hele dokumentet